Antimycotic drugs under continuous renal replacement therapy;Antimykotika unter kontinuierlicher nierenersatztherapie

Mycoses, Supplement

Volumn 48, Issue 1, 2005, Pages 56-60

  Muhl, Elke ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Antimycotic chemotherapy; Hemofiltration; Pharmacokinetics; Renal failure

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; VORICONAZOLE;

CANDIDIASIS; CONFERENCE PAPER; CRITICAL ILLNESS; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG ELIMINATION; DRUG METABOLISM; DRUG PROTEIN BINDING; HEMODIALYSIS; HEMOFILTRATION; HUMAN; KIDNEY FAILURE; MOLECULAR WEIGHT; MYCOSIS; NEPHROTOXICITY; PRIORITY JOURNAL; TREATMENT FAILURE;

ANTIFUNGAL AGENTS; HEMOFILTRATION; HUMANS; METABOLIC CLEARANCE RATE; RENAL REPLACEMENT THERAPY;

EID: 17844393124     PISSN: 09437312     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (24)

1. Maschmeyer G, Ruhnke M. Update on antifungal treatment of invasive Candida and Aspergillus infections. Mycoses 2004; 47: 263-76.
2. Heering P, Brause M. Therapie des akuten Nierenversagens-Fußangeln der Therapie. Intensivmed 2003; 40: 361-8.
3. Kunin CM. A guide to use of antibiotics in patients with renal disease. A table of recommended doses and factors governing serum levels. Arch Intern Med 1967; 67: 151-8.
4. Czock D, Keller F, Thalhammer F. Medikamentendosierung bei kontinuierlicher Hämofiltration. Intensivmed 2003; 40: 369-81.
5. Carlson MA, Condon RE. Nephrotoxicity of amphotericin B. J Am Coll Surg 1994, 179: 361-81.
6. Bennet JE. Antimicrobial agents: Antifungal Agents. In: Hardman JG et al. (eds). Goodman and Gilman's The pharmacological basis of therapeutics. 9th edn. New York: McGraw Hill, 1996: 1175-90.
7. Walsh TJ, Teppler H, Donowitz GR et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351: 1391-402.
8. Leenders ACAP, Daenen S, Jansen RLH et al. Liposomal amphotericin B compared with amphotericin B desoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol 1998; 103: 205-12.
9. Rex JH, Walsh TJ, Sobel JD et al. Practice guidelines for the treatment of candidiasis. Clin Infect Dis 2000; 30: 662-78.
10. Sharkey PK, Rinaldi MG, Dunn JF, Hardin TC, Fetchick RJ, Graybill JR. High dose itraconazole in the treatment of severe mycoses. Antimicrob Agents Chemother 1991; 35: 707-13.
11. Cousin L, LeBerre M, Launay-Vacher V, Izzedine H, Deray G. Dosing guidelines for fluconazole in patients with renal failure. Nephrol Dial Transplant 2003; 18: 2227-31.
12. Bohler J, Donauer J, Keller F. Pharmacokinetic principles during continuous renal replacement therapy: drugs and dosage. Kidney Int 1999; 56 (Suppl. 72): S24-8.
13. Scherz M, Ferdinande P, Van den Berghe G, Verwaest C, Lauwers P. Pharmacokinetics of continuous renal replacement therapy. Intensive Care Med 1995; 21: 612-20.
14. Bellmann R, Egger P, Djanani A, Wiedermann CJ. Pharmacokinetics of amphotericin B lipid complex in critically ill patients on continuous veno-venous haemofiltration. Int J Antimicrob Agents 2004; 23: 80-83.
15. Humphreys H, Oliver DA, Winter R, Warnock DW. Liposomal amphotericin B and continuous veno-venous haemofiltration. J Antimicrob Chemother 1994; 33: 1070-1.
16. Coronel B, Persat F, Dorez D, Moskovtchenko JF, Peins MA, Mercatello A. Itraconazole concentrations during continuous haemodiafiltration. J Antimicrob Chemother 1994; 34: 448-9.
17. Robatel C, Rusca M, Padoin C, Marchetti O, Liaudet L, Buclin T. Disposition of voriconazole during continuous veno-venous haemodiafiltration (CVVHDF) in a single Patient. J Antimicrob Chemother 2004; 54: 269-70.
18. Pittrow L, Penk A. Dosage adjustment of fluconazole during continuous renal replacement therapy. Mycoses 1999; 42: 17-19.
19. Muhl E, Martens T, Iven H, Rob P, Bruch HP. Influence of continuous veno-venous haemodiafiltration and continuous veno-venous haemofiltration on the pharmacokinetics of fluconazole. Eur J Clin Pharmacol 2000; 56: 671-8.
20. Debruyne D. Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses. Clin Pharmacokinet 1997; 33: 52-77.
21. Valtonen M, Tiula E, Neuvonen PJ. Effect of continuous venovenous haemofiltration and haemodiafiltration on the elimination of fluconazole in patients with acute renal failure. J Antimicrob Chemother 1997; 40: 695-700.
22. Hughes CE, Bennett RY, Tuna IC, Beggs WH. Activities of fluconazole and ketoconazole against ketoconazole susceptable and resistant Candida albicans. Antimicrob Agents Chemother 1988; 32: 209-12.
23. Rogers TE, Galgiani J. Activity of fluconazole and ketoconazole against Candida albicans in vitro and in vivo. Antimicrob Agents Chemother 1986; 30: 418-22.
24. Reetze-Bonorden P, Bohler J, Keller E. Drug dosage in patients during continuous renal replacement therapy. Clin Pharmacokinet 1993; 24: 362-79.